Returns as of 12/14/2021
Returns as of 12/14/2021
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Motley Fool Issues Rare “All In” Buy Alert
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Shares of several leading COVID-19 vaccine makers were jumping as of 10:44 a.m. ET on Monday. BioNTech ( BNTX -0.65% ) stock was up 6.2%. Shares of Moderna ( MRNA 1.47% ) were rising 5.7% higher. Novavax ( NVAX -0.80% ) stock was trailing not too far behind, with a 3.8% gain.
There was one common denominator behind the rise of these vaccine stocks. On Sunday, United Kingdom Prime Minister Boris Johnson warned that a “tidal wave” of COVID-19 cases in the country stemming from the omicron variant could be on the way. The U.K. is accelerating its booster program. Investors could be anticipating that other countries could be on a similar path.
In addition, two of the vaccine makers had other news that helped fuel their gains. Results from an Israeli study announced on Saturday appeared to confirm that a third shot of the COVID-19 vaccine developed by BioNTech and Pfizer ( PFE 0.43% ) could provide significant protection from the omicron variant. BioNTech and Pfizer announced laboratory study results last week that showed similar findings.
Novavax announced on Monday morning that it has filed for emergency use of its COVID-19 vaccine in the United Arab Emirates. The company also stated that it remains on track to file for U.S. Emergency Use Authorization (EUA) by the end of this month.
Image source: Getty Images.
The greater the fears are about the omicron variant, the higher these stocks are likely to go. That’s especially the case if there are solid reasons to expect that the companies will secure additional deals to supply more doses of their respective COVID-19 vaccines.
At this point, though, it’s uncertain whether or not any of the vaccine makers will actually sell more doses as a result of the omicron variant. No one knows just how bad the new coronavirus strain will be, although it makes sense for countries such as the U.K. to brace for the worst.
In one way, the Israeli study data isn’t helpful to BioNTech’s and Pfizer’s hopes to sell more doses of their vaccine. If a third booster wasn’t very effective against the omicron variant, the prospects for a new vaccine version specifically targeting the variant would be significantly higher. This would likely be a more lucrative scenario for the companies, especially if two doses were required with the new vaccine version.
As for Novavax’s news, the potential for winning emergency authorization in the United Arab Emirates wouldn’t move the needle all that much for the company. However, investors are almost certainly feeling better that the U.S. EUA filing will be on schedule with Novavax confirming their anticipated submission yet again.
The main thing for investors to watch with all of these companies is whether or not they land additional supply deals. Until there’s money on the table, the up-and-down swings related to the omicron variant merely reflect speculation.
Of the three stocks, Novavax has the most potential catalysts over the near term. The company awaits regulatory authorizations and approvals in multiple countries. It also has the important U.S. EUA filing on the way.
Why do we invest this way? Learn More
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Market-beating stocks from our award-winning service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/14/2021.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns as of January 1, 2021.
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool’s premium services.
Making the world smarter, happier, and richer.
Market data powered by Xignite.